XENERA-1: a Randomised Double-blind Phase II Trial of Xentuzumab in Combination with Everolimus and Exemestane Versus Everolimus and Exemestane in Patients with Hormone Receptor-positive/HER2-negative Metastatic Breast Cancer and Non-visceral Disease

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2023 Jun 12

PMID 37308971

Authors

Peter Schmid

Javier Cortes

Ana Joaquim

Noelia Martinez Janez

Serafin Morales

Tamara Diaz-Redondo

Sibel Blau

Patrick Neven

Julie Lemieux

Jose Angel Garcia-Saenz

Lowell Hart

Tsvetan Biyukov

Navid Baktash

Dan Massey

Howard A Burris 3rd

Hope S Rugo

Affiliations

Soon will be listed here.

Abstract

Background: Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of xentuzumab to everolimus and exemestane in patients with advanced breast cancer with non-visceral disease.

Methods: This double-blind, randomised, Phase II study was undertaken in female patients with hormone-receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative advanced breast cancer with non-visceral disease who had received prior endocrine therapy with or without CDK4/6 inhibitors. Patients received a weekly intravenous infusion of xentuzumab (1000 mg) or placebo in combination with everolimus (10 mg/day orally) and exemestane (25 mg/day orally). The primary endpoint was progression-free survival (PFS) per independent review.

Results: A total of 103 patients were randomised and 101 were treated (n = 50 in the xentuzumab arm and n = 51 in the placebo arm). The trial was unblinded early due to high rates of discordance between independent and investigator assessment of PFS. Per independent assessment, median PFS was 12.7 (95% CI 6.8-29.3) months with xentuzumab and 11.0 (7.7-19.5) months with placebo (hazard ratio 1.19; 95% CI 0.55-2.59; p = 0.6534). Per investigator assessment, median PFS was 7.4 (6.8-9.7) months with xentuzumab and 9.2 (5.6-14.4) months with placebo (hazard ratio 1.23; 95% CI 0.69-2.20; p = 0.4800). Tolerability was similar between the arms, with diarrhoea (33.3-56.0%), fatigue (33.3-44.0%) and headache (21.6-40.0%) being the most common treatment-emergent adverse events. The incidence of grade ≥ 3 hyperglycaemia was similar between the xentuzumab (2.0%) and placebo (5.9%) arms.

Conclusions: While this study demonstrated that xentuzumab could be safely combined with everolimus and exemestane in patients with HR-positive/HER2-negative advanced breast cancer with non-visceral disease, there was no PFS benefit with the addition of xentuzumab. Trial registration ClinicalTrials.gov, NCT03659136. Prospectively registered, September 6, 2018.

Citing Articles

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors.

Pathak N, Mittal A, Kumar S, Nagpal C, Amir E, Haldar P Curr Oncol. 2025; 32(1).

PMID: 39851969 PMC: 11763720. DOI: 10.3390/curroncol32010053.

Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16).

Clarke N, Wong B, Lawrance R, Ingelgard A, Griebsch I, Cella D J Patient Rep Outcomes. 2024; 8(1):97.

PMID: 39145900 PMC: 11327234. DOI: 10.1186/s41687-024-00776-y.

Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer.

Browne I, Okines A Cancers (Basel). 2024; 16(12).

PMID: 38927964 PMC: 11201395. DOI: 10.3390/cancers16122259.

Extracellular Interactors of the IGF System: Impact on Cancer Hallmarks and Therapeutic Approaches.

Mancarella C, Morrione A, Scotlandi K Int J Mol Sci. 2024; 25(11).

PMID: 38892104 PMC: 11172729. DOI: 10.3390/ijms25115915.

Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development.

Shahid A, Santos S, Lin C, Huang Y Biomedicines. 2024; 12(3).

PMID: 38540176 PMC: 10967781. DOI: 10.3390/biomedicines12030563.

References

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Scagliotti G, Bondarenko I, Blackhall F, Barlesi F, Hsia T, Jassem J . Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol. 2014; 26(3):497-504. DOI: 10.1093/annonc/mdu517. View

Wang P, Mak V, Cheung L . Drugging IGF-1R in cancer: New insights and emerging opportunities. Genes Dis. 2023; 10(1):199-211. PMC: 10066341. DOI: 10.1016/j.gendis.2022.03.002. View

Turner N, Slamon D, Ro J, Bondarenko I, Im S, Masuda N . Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018; 379(20):1926-1936. DOI: 10.1056/NEJMoa1810527. View

Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S . Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res. 2021; 23(1):14. PMC: 7844919. DOI: 10.1186/s13058-021-01394-y. View

Cook M, Al Rabadi L, Kaempf A, Saraceni M, Savin M, Mitri Z . Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. Oncologist. 2020; 26(2):101-106. PMC: 7873317. DOI: 10.1002/onco.13609. View

Bidard F, Kaklamani V, Neven P, Streich G, Montero A, Forget F . Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022; 40(28):3246-3256. PMC: 9553388. DOI: 10.1200/JCO.22.00338. View

Friedbichler K, Hofmann M, Kroez M, Ostermann E, Lamche H, Koessl C . Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther. 2013; 13(2):399-409. DOI: 10.1158/1535-7163.MCT-13-0598. View

Rieunier G, Wu X, Macaulay V, Lee A, Weyer-Czernilofsky U, Bogenrieder T . Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis. Clin Cancer Res. 2019; 25(12):3479-3485. DOI: 10.1158/1078-0432.CCR-18-2697. View

10.

Fassnacht M, Berruti A, Baudin E, Demeure M, Gilbert J, Haak H . Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015; 16(4):426-35. DOI: 10.1016/S1470-2045(15)70081-1. View

11.

Fuchs C, Azevedo S, Okusaka T, Van Laethem J, Lipton L, Riess H . A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol. 2015; 26(5):921-927. PMC: 4804122. DOI: 10.1093/annonc/mdv027. View

12.

Simpson A, Petnga W, Macaulay V, Weyer-Czernilofsky U, Bogenrieder T . Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Target Oncol. 2017; 12(5):571-597. PMC: 5610669. DOI: 10.1007/s11523-017-0514-5. View

13.

Rugo H, Tredan O, Ro J, Morales S, Campone M, Musolino A . A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Res Treat. 2017; 165(3):601-609. PMC: 5709225. DOI: 10.1007/s10549-017-4375-5. View

14.

Hamaoka T, Madewell J, Podoloff D, Hortobagyi G, Ueno N . Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22(14):2942-53. DOI: 10.1200/JCO.2004.08.181. View

15.

Gris-Oliver A, Ibrahim Y, Rivas M, Garcia-Garcia C, Sanchez-Guixe M, Ruiz-Pace F . PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Br J Cancer. 2021; 124(9):1581-1591. PMC: 8076303. DOI: 10.1038/s41416-021-01293-1. View

16.

Cao J, Yee D . Disrupting Insulin and IGF Receptor Function in Cancer. Int J Mol Sci. 2021; 22(2). PMC: 7827299. DOI: 10.3390/ijms22020555. View

17.

Mo H, Renna C, Moore H, Abraham J, Kruse M, Montero A . Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. Clin Breast Cancer. 2021; 22(2):143-148. DOI: 10.1016/j.clbc.2021.10.002. View

18.

Mathias S, Crosby R, Qian Y, Jiang Q, Dansey R, Chung K . Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol. 2011; 9(2):72-8. DOI: 10.1016/j.suponc.2010.12.004. View

19.

Lee J, Tocheny C, Shaw L . The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target. Life (Basel). 2022; 12(12). PMC: 9782138. DOI: 10.3390/life12121992. View

20.

de Bono J, Lin C, Chen L, Corral J, Michalarea V, Rihawi K . Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020; 122(9):1324-1332. PMC: 7188670. DOI: 10.1038/s41416-020-0774-1. View